Survival After Curative Treatment of Muscle-Invasive Bladder Cancer

References

• UICC (Union Internationale contre le Cancer 1987). TNM classification of malignant tumours,4th. UICC, Springer-Verlag, Berlin Heidelberg, Geneva 1987; 5–133
   Google Scholar
• Fosså SD, Ous S., Langmark F., Espetveit S. Survival and pattern of care in bladder cancer. Scand J Urol Nephrol 1992; 26: 131–8
   PubMed Web of Science ®Google Scholar
• Fosså SD, Wffihre H., Aass N., Jacobsen A-B, Olsen D. R., Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. Cancer 1993; 72: 3036–43
   PubMed Web of Science ®Google Scholar
• Wáhre H., Ous S., Klevmark B. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72: 3044–51
   PubMedGoogle Scholar
• Malmström P-U, Rintala E., Wahlqvist R., Hellström P., Hell-Sten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. Nordic Cystectomy Trial I. J Urol 1996, in press
   Google Scholar
• Hall RR for MRC Advanced Bladder Cancer Group Working Party, EORTC GU Group. NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group. Club Urologica Espanol de Tratamiento and Fin Bladder. Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/ EORTC Intercontinental Trial. Proceedings ASCO. 1996, 244
   Google Scholar
• Bloom H. J. G., Hendry W. F., Wallace D. M., Skeet R. G. Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Second report and review (for the Clinical Trials Group Institute of Urology). Br J Urol 1982; 54: 136–51
   PubMedGoogle Scholar
• Herr H. W. Preoperative irradiation with and without chemotherapy as adjuvant to radical cystectomy. Urology 1985; 25: 127–34
   PubMed Web of Science ®Google Scholar
• Anderström C., Johansson S., Nilsson S., Unsgaard B., Wahlqvist L. A randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol 1983; 9: 142–7
   PubMed Web of Science ®Google Scholar
• Parsons J. T., Million R. R. Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys 1988; 14: 797–810
   PubMed Web of Science ®Google Scholar
• Crawford D. E., Das S., Smith J. A. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 1987; 14: 781–7
   PubMed Web of Science ®Google Scholar
• Mameghan H., Fisher R. J., Watt W. H. The management of invasive transitional cell carcinoma of the bladder. Cancer 1992; 69: 2771–8
   PubMed Web of Science ®Google Scholar
• Malmström P-U, Rintala E., Wahlqvist R., Hellström P., Hell-Sten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 1996, in press.
   Google Scholar
• Pollack A., Zagars G. K., Dinney C. P., Swanson D. S., von Eschen-Bach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Cancer 1994; 74: 2819–27
   PubMed Web of Science ®Google Scholar
• Pagano F., Bassi P., Galetti T. P., Meneghini A., Milani C., Artibani W., Garbeglio A. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor nodes and metastases classification. J Urol 1991; 145: 45–50
   PubMed Web of Science ®Google Scholar
• Zincke H., Patterson D. E., Utz D. C., Benson R. C. Pelvic lymphadenectomy and radical cystectomy for transitional cell carcinoma of the bladder with pelvic nodal disease. Br J Urol 1985; 57: 156–9
   PubMedGoogle Scholar
• Smith S. A., Whitmore WF, Jr. Regional lymph node metastasis from bladder cancer. J Urol 1981; 126: 591–3
   PubMed Web of Science ®Google Scholar
• Duncan W., Quilty P. M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986; 7: 299–310
   PubMed Web of Science ®Google Scholar
• Goodman G. B., Hislop T. G., Elwood J. M., Balfour J. Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selected cystectomy. Int J Radiat Oncol Biol Phys 1981; 7: 75–569
   Google Scholar
• Shipley W. U., Rose M. A., Perrone T. L., Mannix C. M., Heney N. M., Prout GR, Jr. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 1985; 134: 679–83
   PubMed Web of Science ®Google Scholar
• Pollack A., Zagars G. K., Swanson D. S. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994; 30: 267–77
   PubMed Web of Science ®Google Scholar
• Matsumoto K., Kakisoe T., Mikuriya S., Tanaka T., Kondo I., Umegaki Y. Clinical evaluation of intraoperative radiotherapy for carcinoma of the urinary bladder. Cancer 1981; 47: 509–13
   PubMedGoogle Scholar
• van der Werf-Messing B. Cancer of the urinary bladder treated by interstitial radium implant. Int J Radiat Oncol Biol Phys 1978; 4: 373–8
   PubMedGoogle Scholar
• Eidsmyr F., Anderson L., Esposti P. L., Littbrand B., Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol 1985; 4: 197–203
   PubMedGoogle Scholar
• Fosså SD, Ous S., Berner Aa. The clinical significance of the ‘palpable mass’ in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol 1991; 67: 54–60
   PubMedGoogle Scholar
• Harker W. G., Meyers F. J., Freiha F. S., Palmer J. M., Shortliffe L. D., Hannigan J. F. Cisplatin, Methotrexate, and Vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 1985; 3: 1463–70
   PubMed Web of Science ®Google Scholar
• Sternberg C., Yagoda A., Scher H. I. Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448–58
   PubMed Web of Science ®Google Scholar
• Splinter T. W. A., Scher H. I., Denis L. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 1992; 147: 606–8
   PubMedGoogle Scholar
• Schultz P. K., Herr H. W., Zhang Z-F. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994; 12: 1394–1401
   PubMedGoogle Scholar
• Dunst J., Sauer R., Schrott K. M. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994; 30: 261–6
   PubMed Web of Science ®Google Scholar
• Roth B. J. Preliminary experience with paclitaxel in advanced bladder cancer. Sem Oncol 1995; 22: 1–5
   PubMedGoogle Scholar
• Moore M. J., Tannock I., Ernst S., Huan S., Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proceedings ASCO. 1996, 250
   Google Scholar
• Stöckle M., Meyenberg W., Wellek S. Advanced bladder cancer (stages pT3b, pT4a, pNl and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 302–7
   PubMed Web of Science ®Google Scholar